Proton Pump Inhibitor Treatment Stop

Status Completed

Clinical Trial Summary

The purpose of this study is to determine how many chronic users of antisecretory medication can stop after a test for a bacteria associated with peptic ulcer disease.

This is evaluated in a discontinuation trial.

Clinical Trial Description

Background:

Testing patients with a Helicobacter pylori (Hp) 13C-urea breath test and treatment with eradication of Hp if positive - test-and-eradicate - have proven as effective and safe as prompt endoscopy for management of dyspeptic patients in a primary health care setting. However, empirical treatment with an ulcer-healing drug is often used in dyspeptic patients, as reflected in a growing proportion of long-term users without known ulcer or gastro-oesophageal reflux disease (GORD). This group of patients contributed to 59% of the total use of acid-suppressive medication in the County of Funen in Denmark in 1997.

Aim/purpose:

It is our aim to examine the need for continued medication with prescribed, acid-suppressive drugs in primary health care.

Our secondary objective is to investigate the profile of symptoms, quality of life, Hp-status, consumption of drugs and use of health care services in the same context.

Methods:

To conduct a randomised, placebo-controlled, blinded, clinical discontinuation trial, 500 long-term users of acid-suppressive drugs are identified by general practitioners. Long-term use is defined as treatment for more than 2x28 days during a 6-month period. The patients are included with a 13C-urea Hp-breath test and randomised for treatment with PPI or placebo. Hp-positive patients are treated with an Hp-eradication treatment. The patients are followed for 1 year; the primary outcome is the need for open treatment with acid-suppressive medication due to failing symptom relief despite treatment with the randomised project medication. The patients are to fill in a symptom and medication diary every month for periods of 1 week. Questionnaires are to be given to the patients 3 times during the follow-up period. Medication diaries as well as questionnaires have proven useful in similar studies. The main outcome is analysed using Kaplan-Meier survival estimates analysis. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Dyspepsia

Clinical Trial Details

NCT number	NCT00120315
Study type	Interventional
Source	Odense University Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	December 2003
Completion date	March 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06094062` - Smartphone App-assisted PPI	N/A
Completed	`NCT03941288` - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia	Phase 2
Completed	`NCT04429802` - The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity	N/A
Not yet recruiting	`NCT06369753` - Visible Abdominal Distension	N/A
Withdrawn	`NCT02863822` - Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.	N/A
Recruiting	`NCT00978159` - Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia	Phase 4
Completed	`NCT00723502` - Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients	Phase 2
Terminated	`NCT00220844` - Tricyclic Antidepressants (TCAs) on Gastric Emptying	N/A
Completed	`NCT00217347` - Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy	N/A
Completed	`NCT00148603` - Montelukast in the Treatment of Duodenal Eosinophilia	N/A
Completed	`NCT00164996` - Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia	Phase 3
Completed	`NCT00110968` - Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia	Phase 3
Completed	`NCT00232037` - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia	Phase 3
Completed	`NCT00232102` - Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia	Phase 3
Recruiting	`NCT05718960` - Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia	N/A
Completed	`NCT05750641` - The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
Terminated	`NCT04247100` - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders	N/A
Completed	`NCT03252743` - ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.	N/A
Completed	`NCT04697641` - Helicobacter Pylori Eradication in Functional Dyspepsia	N/A
Recruiting	`NCT04918329` - Functional Digestive Disorders Observatory

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.